Curasight Curasight is a company engaged in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). | Microvascular Therapeutics Microvascular Therapeutics (MVT) is a biotechnology company engaged in the development of an ultrasound contrast agent, MVT-100. | ||||
Founding Date | Founding Date 2003 | Founding Date 2013 | Founding Date 2014 | Founding Date 2016 | Founding Date 2011 |
Type | Type Subsidiary | Type Private | Type Subsidiary | Type Private | Type Private |
Tags | |||||
Locations | Locations Bundoora, AU HQ München, DE Hummelstown, US | Locations København, DK HQ | Locations Oxford, GB HQ Dublin, IE Burlington, US | Locations Tucson, US HQ | Locations Montpellier, FR HQ Grabels, FR |
Employees | Employees 20 | Employees 7 | Employees 1061% decrease | Employees 1220% increase | Employees 614% decrease |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 19.7m | Total funding raised $ 1.6m | Total funding raised N/A |
Curasight is a company engaged in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR).
View company
Blue Earth Diagnostics is a molecular imaging diagnostics company.
View companyMicrovascular Therapeutics (MVT) is a biotechnology company engaged in the development of an ultrasound contrast agent, MVT-100.
View company
SurgiMab is a company that develops of intraoperative detection of tumors.
View company